Search Results - "G. Fountzilas"

Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation by Fountzilas, G., Ciuleanu, E., Bobos, M., Kalogera-Fountzila, A., Eleftheraki, A.G., Karayannopoulou, G., Zaramboukas, T., Nikolaou, A., Markou, K., Resiga, L., Dionysopoulos, D., Samantas, E., Athanassiou, H., Misailidou, D., Skarlos, D., Ciuleanu, T.

“…Concomitant administration of radiation therapy (RT) and chemotherapy with cisplatin (CCRT) is considered standard treatment in patients with locally advanced…”
Get full text

Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis by Pignon, Jean-Pierre, Le, Quynh Thu, Grau, Cai, Hackshaw, Allan, Ghi, Maria Grazia, Sanguineti, Giuseppe, O'Sullivan, Brian, Vokes, Everett E, Cruz Hernandez, Juan J, Budach, Volker, Poulsen, Michael, Kumar, Shaleen, Ghosh Laskar, Sarbani, Mazeron, Jean-Jacques, Simes, John, Zhong, Lai-Ping, Bourhis, Jean, Aupérin, Anne, Agarwal, J., Argiris, A., Aupérin, A., Bacigalupo, A., Belkacemi, Y., Bensadoun, R.J., Bernier, J., Blanchard, P., Bourhis, J., Brizel, D., Budach, V., Burtness, B., Campbell, B., Chabaud, S., Chamorey, E., Chaukar, D., Choussy, O., Cruz Hernandez, J.J., Denham, J.W., Dobrowsky, W., Driessen, C.M.L., Fortpied, C., Garaud, P., Garden, A.S., Ghadjar, P., Ghosh Laskar, S., Grau, C., Gregoire, V., Hackshaw, A., Haffty, B.G., Hansen, A., Hay, J.H., Hayoz, S., Horiot, J.C., Hitt, R., Johansen, J., Julieron, M., Kumar, S., Lacas, B., Langendijk, J.A., Lapeyre, M., Licitra, L., Lee, P., Li, Y., Lotayef, M., Maciejewski, B., Mehta, S., Michalski, W., Moon, J., Moon, S.H., Nilsson, P., Orecchia, R., Parmar, M.K.B., Pointreau, Y., Poulsen, M.G., Quon, H., Rosenthal, D.I., Sanguineti, G., Simes, J., Simon, C., Sire, C., Staar, S., Strojan, P., Suwinski, R., Szutkowski, Z., Takácsi-Nagy, Z., Tao, Y.G., Temam, S., Thomson, D., Torri, V., Tripcony, L., Tseroni, V., van Tinteren, H., Viegas, C.M.P., Vokes, E.E., Waldron, J., Wernecke, K.D, Wolf, G.T., Wong, S.J., Wu, J.S., Zaktonik, B., Zackrisson, B.

“…Randomised, controlled trials and meta-analyses have shown the survival benefit of concomitant chemoradiotherapy or hyperfractionated radiotherapy in the…”
Get full text

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients by Martin, V, Landi, L, Molinari, F, Fountzilas, G, Geva, R, Riva, A, Saletti, P, De Dosso, S, Spitale, A, Tejpar, S, Kalogeras, K T, Mazzucchelli, L, Frattini, M, Cappuzzo, F

“…Background: In metastatic colorectal cancer (mCRC), KRAS is the only validated biomarker used to select patients for administration of epidermal growth factor…”
Get full text

Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study by Psyrri, A., Kalogeras, K.T., Kronenwett, R., Wirtz, R.M., Batistatou, A., Bournakis, E., Timotheadou, E., Gogas, H., Aravantinos, G., Christodoulou, C., Makatsoris, T., Linardou, H., Pectasides, D., Pavlidis, N., Economopoulos, T., Fountzilas, G.

“…The ubiquitin–proteasome system (UPS) plays a pivotal role in tumorigenesis. Components of the UPS have recently been implicated in breast cancer progression…”
Get full text

Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group by Koinis, F, Agelaki, S, Karavassilis, V, Kentepozidis, N, Samantas, E, Peroukidis, S, Katsaounis, P, Hartabilas, E, Varthalitis, I I, Messaritakis, I, Fountzilas, G, Georgoulias, V, Kotsakis, A

“…Background: Pazopanib is a tyrosine kinase inhibitor with antiangiogenic activity. Vascular endothelial growth factor expression is increased in SCLC and is…”
Get full text

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group by André, T., Vernerey, D., Im, S.A., Bodoky, G., Buzzoni, R., Reingold, S., Rivera, F., McKendrick, J., Scheithauer, W., Ravit, G., Fountzilas, G., Yong, W.P., Isaacs, R., Österlund, P., Liang, J.T., Creemers, G.J., Rakez, M., Van Cutsem, E., Cunningham, D., Tabernero, J., de Gramont, A.

“…The bevacizumab-Avastin® adjuVANT (AVANT) study did not meet its primary end point of improving disease-free survival (DFS) with the addition of bevacizumab to…”
Get full text

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer by Razis, E., Bobos, M., Kotoula, V., Eleftheraki, A. G., Kalofonos, H. P., Pavlakis, K., Papakostas, P., Aravantinos, G., Rigakos, G., Efstratiou, I., Petraki, K., Bafaloukos, D., Kostopoulos, I., Pectasides, D., Kalogeras, K. T., Skarlos, D., Fountzilas, G.

“…Trastuzumab (T) is effective in metastatic breast cancer (MBC) with HER2 overexpression and/or amplification, but resistance to T develops in a significant…”
Get full text

Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03) by Bamias, A., Dafni, U., Karadimou, A., Timotheadou, E., Aravantinos, G., Psyrri, A., Xanthakis, I., Tsiatas, M., Koutoulidis, V., Constantinidis, C., Hatzimouratidis, C., Samantas, E., Visvikis, A., Chrisophos, M., Stravodimos, K., Deliveliotis, C., Eleftheraki, A., Pectasides, D., Fountzilas, G., Dimopoulos, M.A.

“…The combinations of methotrexate, vinblastine, Adriamycin, cisplatin (Pharmanell, Athens, Greece) (MVAC) or gemcitabine, cisplatin (GC) represent the standard…”
Get full text

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer by STATHOPOULOS, G. P, SYRIGOS, K, ANDROULAKIS, N, KOTSAKIS, A, SAMONIS, G, GEORGOULIAS, V, ARAVANTINOS, G, POLYZOS, A, PAPAKOTOULAS, P, FOUNTZILAS, G, POTAMIANOU, A, ZIRAS, N, BOUKOVINAS, J, VARTHALITIS, J

“…Our purpose was to determine the response rate and median and overall survival of gemcitabine as monotherapy versus gemcitabine plus irinotecan in advanced or…”
Get full text

Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial by Pliarchopoulou, K., Kalogeras, K. T., Kronenwett, R., Wirtz, R. M., Eleftheraki, A. G., Batistatou, A., Bobos, M., Soupos, N., Polychronidou, G., Gogas, H., Samantas, E., Christodoulou, C., Makatsoris, T., Pavlidis, N., Pectasides, D., Fountzilas, G.

“…Purpose RACGAP1 is a Rac GTPase-activating protein involved in cell growth regulation, cell transformation and metastasis. The aim of the present study was to…”
Get full text

Haplotype analysis reveals that the recurrent BRCA1 deletion of exons 23 and 24 is a Greek founder mutation by Apostolou, P., Pertesi, M., Aleporou‐Marinou, V., Dimitrakakis, C., Papadimitriou, C., Razis, E., Christodoulou, C., Fountzilas, G., Yannoukakos, D., Konstantopoulou, I., Fostira, F.

“…A recurrent large genomic rearrangement (LGR) encompassing exons 23 and 24 of the BRCA1 gene has been identified in breast‐ovarian cancer families of Greek…”
Get full text

A phase II window of opportunity study of preoperative olaparib (O) with cisplatin (C) or durvalumab (D) or olaparib alone in in patients with operable squamous cell head and neck carcinoma (HNSCC) (OPHELIA) by Psyrri, A., Economopoulou, P., Kotsantis, I., Koutsodontis, G., Cheila, M., Papaxoinis, G., Pectasides, D.G., Fountzilas, G., Krikoni, L., Souliotis, V.

Get full text

Evaluation of the efficacy and safety of everolimus as a first-line treatment in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors by Koumarianou, A., Pectasides, D.G., Manousou, K., Dionysopoulos, D., Kaltsas, G.A., Kolomodi, D., Poulios, C., Skondra, M., Samantas, E., Pentheroudakis, G., Fountzilas, G.

Get full text

Afatinib in combination with cisplatin and 5-fluorouracil (5-FU) as first line treatment in inoperable gastric and gastro-esophageal junction (GEJ) cancer: A phase II study by the Hellenic Cooperative Oncology Group by Makatsoris, T., Samantas, E., Manousou, K., Karavasilis, V., Aravantinos, G., Tryfonopoulos, D., Psyrri, A., Pectasides, D.G., Pazarli, E., Petraki, C., Tsipoura, A., Kaklamanos, I.G., Fountzilas, G., Pentheroudakis, G.

Get full text

randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer by Bamias, Aristotelis, Karina, M, Papakostas, P, Kostopoulos, I, Bobos, M, Vourli, G, Samantas, E, Christodoulou, Ch, Pentheroudakis, G, Pectasides, D, Dimopoulos, M. A, Fountzilas, G

“…The optimal adjuvant treatment for gastric cancer remains controversial. We compared the efficacy of a docetaxel and platinum adjuvant chemotherapy regimen, in…”
Get full text

Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial by Karthaus, M., Kretzschmar, A., Kröning, H., Biakhov, M., Irwin, D., Marschner, N., Slabber, C., Fountzilas, G., Garin, A., Abecasis, N.G.F., Baronius, W., Steger, G.G., Südhoff, T., Giorgetti, C., Reichardt, P.

“…Background: Cancer patients receiving chemotherapy experience thromboembolic complications associated with the use of long-term indwelling central venous…”
Get full text

Primary fallopian tube carcinoma: Results of a retrospective analysis of 64 patients by Pectasides, D, Pectasides, E, Papaxoinis, G, Andreadis, C, Papatsibas, G, Fountzilas, G, Pliarchopoulou, K, Macheras, A, Aravantinos, G, Economopoulos, T

“…Abstract Objective The objective of this retrospective study was to determine the clinical outcomes of patients with primary fallopian tube carcinoma (PFTC)…”
Get full text

Carboplatin and paclitaxel in advanced or metastatic endometrial cancer by Pectasides, D, Xiros, N, Papaxoinis, G, Pectasides, E, Sykiotis, C, Koumarianou, A, Psyrri, A, Gaglia, A, Kassanos, D, Gouveris, P, Panayiotidis, J, Fountzilas, G, Economopoulos, T

“…Abstract Objectives The purpose of this study was to evaluate the activity and toxicity of carboplatin and paclitaxel combination in advanced or recurrent…”
Get full text

Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype by Rampias, T., Pectasides, E., Prasad, M., Sasaki, C., Gouveris, P., Dimou, A., Kountourakis, P., Perisanidis, C., Burtness, B., Zaramboukas, T., Rimm, D., Fountzilas, G., Psyrri, A.

“…We sought to determine biomarker expression differences in head and neck squamous cell cancers (HNSCCs) based on p16/human papillomavirus (HPV) classification…”
Get full text

Real-world efficacy and toxicity data of paclitaxel and ramucirumab compared with other treatment regimens in patients with advanced gastric cancer by E. Fountzilas, J. Souglakos, J. Alafis, K. Dadouli, A. Koumarianou, N. Tsoukalas, A. Nikolaidi, D. Mauri, M. Karagianni, A. Anna, A. Psyrri, G. Rigakos, A. Avgerinos, M. Theochari, D. Pectasides, G. Oikonomopoulos, A. Vagionas, P. Papakostas, A. Christopoulou, G. Fountzilas, Z. Saridaki

“…Background: The superiority of paclitaxel/ramucirumab over alternative therapeutic regimens in patients with gastric cancer has yet to be defined. Our aim was…”
Get full text